Harbin Gloria Pharmaceuticals Net Asset Quality Index
Harbin Gloria Pharmaceuticals net asset quality index. Harbin Gloria Pharmaceuticals (002437) has a Net Asset Quality Index of 76.6% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥3.14 Billion minus total liabilities of CN¥735.96 Million yields net assets of CN¥2.41 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See Harbin Gloria Pharmaceuticals shareholders equity for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Harbin Gloria Pharmaceuticals (2007–2025)
Net asset quality index of Harbin Gloria Pharmaceuticals from 2007 to 2025. This chart shows how Harbin Gloria Pharmaceuticals's Net Asset Quality Index has evolved across 19 annual periods from 2007 to 2025. As of March 2026, the index stands at 76.6%, representing net assets of CN¥2.41 Billion against total assets of CN¥3.14 Billion CNY. Check Harbin Gloria Pharmaceuticals strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Harbin Gloria Pharmaceuticals Net Asset Quality Index by Year (2007–2025)
Harbin Gloria Pharmaceuticals net asset quality index by year from 2007 to 2025. The table below presents the year-by-year Net Asset Quality Index for Harbin Gloria Pharmaceuticals from 2007 to 2025, covering 19 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Harbin Gloria Pharmaceuticals stock valuation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 73.7% | CN¥2.31 Billion | CN¥3.13 Billion | CN¥825.00 Million | ▲ +3.8 pp |
| 2024 | 69.8% | CN¥1.97 Billion | CN¥2.83 Billion | CN¥852.26 Million | ▲ +15.6 pp |
| 2023 | 54.3% | CN¥1.71 Billion | CN¥3.15 Billion | CN¥1.44 Billion | ▲ +12.4 pp |
| 2022 | 41.8% | CN¥1.70 Billion | CN¥4.07 Billion | CN¥2.37 Billion | ▼ -0.3 pp |
| 2021 | 42.1% | CN¥1.98 Billion | CN¥4.70 Billion | CN¥2.72 Billion | ▼ -0.7 pp |
| 2020 | 42.8% | CN¥1.93 Billion | CN¥4.52 Billion | CN¥2.58 Billion | ▲ +18.0 pp |
| 2019 | 24.8% | CN¥1.59 Billion | CN¥6.41 Billion | CN¥4.82 Billion | ▼ -21.6 pp |
| 2018 | 46.4% | CN¥4.39 Billion | CN¥9.48 Billion | CN¥5.08 Billion | ▼ -0.6 pp |
| 2017 | 46.9% | CN¥4.25 Billion | CN¥9.06 Billion | CN¥4.81 Billion | ▲ +0.2 pp |
| 2016 | 46.7% | CN¥4.05 Billion | CN¥8.67 Billion | CN¥4.62 Billion | ▲ +4.9 pp |
| 2015 | 41.7% | CN¥3.47 Billion | CN¥8.32 Billion | CN¥4.85 Billion | ▼ -21.3 pp |
| 2014 | 63.0% | CN¥3.10 Billion | CN¥4.92 Billion | CN¥1.82 Billion | ▼ -21.2 pp |
| 2013 | 84.2% | CN¥2.48 Billion | CN¥2.94 Billion | CN¥464.60 Million | ▼ -7.8 pp |
| 2012 | 92.1% | CN¥2.36 Billion | CN¥2.56 Billion | CN¥203.79 Million | ▼ -3.0 pp |
| 2011 | 95.0% | CN¥2.20 Billion | CN¥2.31 Billion | CN¥114.91 Million | ▼ -1.6 pp |
| 2010 | 96.6% | CN¥2.12 Billion | CN¥2.19 Billion | CN¥73.73 Million | ▲ +31.7 pp |
| 2009 | 65.0% | CN¥287.53 Million | CN¥442.48 Million | CN¥154.95 Million | ▼ -4.5 pp |
| 2008 | 69.5% | CN¥194.04 Million | CN¥279.21 Million | CN¥85.17 Million | ▲ +5.3 pp |
| 2007 | 64.2% | CN¥138.36 Million | CN¥215.51 Million | CN¥77.15 Million | — |